BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fondevila F, Méndez-Blanco C, Fernández-Palanca P, González-Gallego J, Mauriz JL. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp Mol Med 2019;51:1-15. [PMID: 31551425 DOI: 10.1038/s12276-019-0308-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma SX, Li L, Cai H, Guo TK, Zhang LS. Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review. World J Clin Oncol 2023; 14(2): 81-88 [DOI: 10.5306/wjco.v14.i2.81] [Reference Citation Analysis]
2 Bandi SP, Datta D, Venuganti VVK. Hydrocaffeic acid-chitosan coating of gastric patch provides long-acting mucoadhesive delivery of model chemotherapeutic agent. Int J Pharm 2023;631:122504. [PMID: 36529359 DOI: 10.1016/j.ijpharm.2022.122504] [Reference Citation Analysis]
3 Shahidi S, Rostamizadeh K, Fathi M, Nedaei K, Ramazani A. Combination of Quercetin or/and siRNA-loaded DDAB-mPEG-PCL hybrid nanoparticles reverse resistance to Regorafenib in colon cancer cells. BMC Complement Med Ther 2022;22:340. [PMID: 36575448 DOI: 10.1186/s12906-022-03787-8] [Reference Citation Analysis]
4 Haque E, Muhsen IN, Esmail A, Umoru G, Mylavarapu C, Ajewole VB, Abdelrahim M. Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer. Front Oncol 2022;12:992455. [PMID: 36620581 DOI: 10.3389/fonc.2022.992455] [Reference Citation Analysis]
5 Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A. Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance. Cells 2022;11. [PMID: 36429091 DOI: 10.3390/cells11223663] [Reference Citation Analysis]
6 Cidre-Aranaz F, Watson S, Amatruda JF, Nakamura T, Delattre O, de Alava E, Dirksen U, Grünewald TGP. Small round cell sarcomas. Nat Rev Dis Primers 2022;8:66. [PMID: 36202860 DOI: 10.1038/s41572-022-00393-3] [Reference Citation Analysis]
7 Hameedat F, Pizarroso NA, Teixeira N, Pinto S, Sarmento B. Functionalized FcRn-targeted nanosystems for oral drug delivery: A new approach to colorectal cancer treatment. Eur J Pharm Sci 2022;176:106259. [PMID: 35842140 DOI: 10.1016/j.ejps.2022.106259] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Afonso M, Brito MA. Therapeutic Options in Neuro-Oncology. Int J Mol Sci 2022;23:5351. [PMID: 35628161 DOI: 10.3390/ijms23105351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chang Y, Li C, Chan M, Chen M, Yeh C, Hsiao M. Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis. Cell Death Dis 2022;13:391. [DOI: 10.1038/s41419-022-04816-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Gaudino S, Marziali G, Giordano C, Gigli R, Varcasia G, Magnani F, Chiesa S, Balducci M, Costantini AM, Della Pepa GM, Olivi A, Russo R, Colosimo C. Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes. Front Radio 2022;1. [DOI: 10.3389/fradi.2021.790456] [Reference Citation Analysis]
11 Vempati RK, Malla RR. Targeting hepatocellular carcinoma by small-molecule inhibitors. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00012-4] [Reference Citation Analysis]
12 Lahooti B, Poudel S, Mikelis CM, Mattheolabakis G. MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential. Front Oncol 2021;11:705634. [PMID: 34956857 DOI: 10.3389/fonc.2021.705634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Sun EJ, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines 2021;9:1639. [PMID: 34829868 DOI: 10.3390/biomedicines9111639] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
14 Fondevila F, Méndez-Blanco C, Fernández-Palanca P, Payo-Serafín T, van Pelt J, Verslype C, González-Gallego J, Mauriz JL. Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib. Int J Mol Sci 2021;22:11770. [PMID: 34769197 DOI: 10.3390/ijms222111770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Pyo J, Park HJ. Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3599. [PMID: 34441895 DOI: 10.3390/jcm10163599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer 2021:S1533-0028(21)00071-2. [PMID: 34404621 DOI: 10.1016/j.clcc.2021.07.006] [Reference Citation Analysis]
17 Dahiya M, Dureja H. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. J Chemother 2021;:1-16. [PMID: 34291704 DOI: 10.1080/1120009X.2021.1955202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Nwagwu CD, Adamson DC. Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma? Expert Opin Pharmacother 2021;:1-12. [PMID: 34219576 DOI: 10.1080/14656566.2021.1950139] [Reference Citation Analysis]
19 Wang K, Yu G, Lin J, Wang Z, Lu Q, Gu C, Yang T, Liu S, Yang H. Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs. Front Pharmacol 2021;12:632201. [PMID: 34220494 DOI: 10.3389/fphar.2021.632201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, Choulier L. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers (Basel) 2021;13:1795. [PMID: 33918704 DOI: 10.3390/cancers13081795] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
21 Tsai TH, Chen YJ, Wang LY, Hsieh CH. Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation. Pharmaceutics 2021;13:386. [PMID: 33805831 DOI: 10.3390/pharmaceutics13030386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A, Shivakumar P. "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front Oncol 2020;10:627701. [PMID: 33718121 DOI: 10.3389/fonc.2020.627701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
23 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
24 Taslimi S, Ye VC, Wen PY, Zadeh G. Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma. Neurooncol Adv 2021;3:vdab029. [PMID: 34042101 DOI: 10.1093/noajnl/vdab029] [Reference Citation Analysis]
25 Méndez-Blanco C, Fernández-Palanca P, Fondevila F, González-Gallego J, Mauriz JL. Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis. Ther Adv Med Oncol 2021;13:1758835920987071. [PMID: 33613697 DOI: 10.1177/1758835920987071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
26 Fernández-Palanca P, Méndez-Blanco C, Fondevila F, Tuñón MJ, Reiter RJ, Mauriz JL, González-Gallego J. Melatonin as an Antitumor Agent against Liver Cancer: An Updated Systematic Review. Antioxidants (Basel) 2021;10:103. [PMID: 33445767 DOI: 10.3390/antiox10010103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
27 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
28 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 23.5] [Reference Citation Analysis]
29 Solano LN, Nelson GL, Ronayne CT, Jonnalagadda S, Jonnalagadda SK, Kottke K, Chitren R, Johnson JL, Pandey MK, Jonnalagadda SC, Mereddy VR. Synthesis, in vitro, and in vivo evaluation of novel N-phenylindazolyl diarylureas as potential anti-cancer agents. Sci Rep 2020;10:17969. [PMID: 33087745 DOI: 10.1038/s41598-020-74572-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
30 Lizardo DY, Kuang C, Hao S, Yu J, Huang Y, Zhang L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev Cancer 2020;1874:188447. [PMID: 33035640 DOI: 10.1016/j.bbcan.2020.188447] [Cited by in Crossref: 34] [Cited by in F6Publishing: 44] [Article Influence: 11.3] [Reference Citation Analysis]
31 Mishima S, Kawazoe A, Shitara K. Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine. Expert Opin Drug Saf 2020;19:1063-8. [PMID: 32741230 DOI: 10.1080/14740338.2020.1805428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Liu YC, Tsai JJ, Weng YS, Hsu FT. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer. Biomed Pharmacother 2020;128:110319. [PMID: 32502841 DOI: 10.1016/j.biopha.2020.110319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
33 Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol 2020;12:1758835920927602. [PMID: 32518599 DOI: 10.1177/1758835920927602] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
34 Li W, He Y, Chen W, Man W, Fu Q, Tan H, Guo H, Zhou J, Yang P. Knockdown of LINC00467 contributed to Axitinib sensitivity in hepatocellular carcinoma through miR-509-3p/PDGFRA axis. Gene Ther. [DOI: 10.1038/s41434-020-0137-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
35 Cucarull B, Tutusaus A, Subías M, Stefanovic M, Hernáez-Alsina T, Boix L, Reig M, García de Frutos P, Marí M, Colell A, Bruix J, Morales A. Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. Cancers (Basel) 2020;12:E332. [PMID: 32024199 DOI: 10.3390/cancers12020332] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
36 Leite RMDA, Demarchi I, Bonatti TR, Faculty of Medicine of Jundiaí, Jundiaí, Brazil, Nove de Julho University, São Paulo, Brazil, Paulista University, Campinas, Brazil. Regorafenib – Five Years in Review. European Oncology & Haematology 2020;16:24. [DOI: 10.17925/eoh.2020.16.1.24] [Reference Citation Analysis]
37 Fernández-Palanca P, Fondevila F, Méndez-Blanco C, Tuñón MJ, González-Gallego J, Mauriz JL. Antitumor Effects of Quercetin in Hepatocarcinoma In Vitro and In Vivo Models: A Systematic Review. Nutrients 2019;11:E2875. [PMID: 31775362 DOI: 10.3390/nu11122875] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
38 Booth L, Poklepovic A, Dent P. Not the comfy chair! Cancer drugs that act against multiple active sites. Expert Opin Ther Targets 2019;23:893-901. [PMID: 31709855 DOI: 10.1080/14728222.2019.1691526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]